logo
logo
Sign in

The Global Myocardial Infarction Market Growth Accelerated By Rising Prevalence Of Cardiovascular Diseases

avatar
Leena Shedmake
The Global Myocardial Infarction Market Growth Accelerated By Rising Prevalence Of Cardiovascular Diseases

Myocardial infarction, commonly known as heart attack, occurs due to the blockage of blood supply to the heart muscles. Heart attacks are caused primarily due to conditions like coronary artery disease, hypertension, high cholesterol, obesity, smoking, and diabetes. The rising prevalence of these cardiovascular diseases and risk factors is resulting in increased number of heart attacks worldwide. For instance, according to the American Heart Association (AHA), in the United States alone, around 950,000 people have heart attacks annually. The global myocardial infarction market largely revolves around the treatment and management of heart attacks. Drugs like antiplatelets, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, statins, and angiotensin II receptor blockers (ARBs) are commonly prescribed after a heart attack to prevent future cardiac events.

The global myocardial infarction market is estimated to be valued at US$ 2037.51 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market key trends:


One of the major trends fueling the growth of the myocardial infarction market is rising research in the field of regenerative therapies. Researchers are exploring the potential of stem cell therapy for myocardial repair after heart attacks. Mesenchymal stem cells extracted from bone marrow, adipose tissue and others have shown promising therapeutic effects in pre-clinical and clinical trials by reducing cardiac fibrosis and improving cardiac function post-infarction. Promising results from ongoing research studies are expected to translate some of these regenerative therapies into approved clinical therapies over the forecast period, which would significantly help in heart muscle repair and accelerate market growth.


Segment Analysis


The global myocardial infarction market is dominated by the drugs sub segment. Drugs used for the treatment of myocardial infarction provide immediate relief and minimize the damage to the heart muscles. Drugs offer critical care for heart attack patients and have higher adoption rates than other treatments like surgeries or medical devices.


Key Takeaways


The Global Myocardial Infarction Market Demand is expected to witness high growth during the forecast period of 2023 to 2030. The market size for 2023 is estimated to be US$ 2037.51 Mn.


Regional analysis

North America region currently holds the largest share in the global myocardial infarction market owing to growing prevalence of cardiovascular diseases, well developed healthcare infrastructure and availability of advanced treatments. The region is expected to maintain its dominance during the forecast period as well. Asia Pacific region is expected to witness the fastest growth during the forecast period due to rise in geriatric population, changing lifestyles and improving healthcare facilities in emerging economies.


Key players

Key players operating in the myocardial infarction market are Bristol-Myers Squibb Co., Bayer AG, Johnson & Johnson Services Inc., Sanofi S.A., Novartis International AG, AstraZeneca plc., Daiichi Sankyo Co Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc., and Merck KGaA. These players are focusing on new product approvals and launches to strengthen their market position.

 

Explorer more information on this topic, Please visit -


https://www.marketwebjournal.com/myocardial-infarction-market-growth-and-trnds-analysis-share-size-demand-forecast/

collect
0
avatar
Leena Shedmake
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more